← Back
Moleculin Biotech
MBRX · listed on Nasdaq · worth $8.47 million
$8.46
+1.93% today
No insider bought or sold Moleculin Biotech stock on the market in the last year.
◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
2 reverse splits here, the latest 1-for-20 in Oct 2026. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what MBRX ever actually traded at. The drop is real, but those huge old numbers aren't.
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
838.7K shares
82% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
No insider bought or sold Moleculin Biotech stock on the market in the last year. The reports below are share awards and other paperwork.
Big investors
People and funds that reported owning 5% or more of Moleculin Biotech, newest first.
Filed by someone who owns 5% or more and may try to influence how the company is run.Foster Jonathan P.6.3%Aug 25
Filed by someone who owns 5% or more and may try to influence how the company is run.Klemp Walter V9.9%Aug 25
Filed by someone who owns 5% or more and does not plan to influence the company.CVI Investments9.9%Aug 10
Filed by someone who owns 5% or more and does not plan to influence the company.Intracoastal Capital5.0%Aug 6
All reports
Every insider trade and SEC report we hold for Moleculin Biotech.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Jun 23, 2025BoughtJonathan P. FosterJun 23, 2025 · Chief Financial Officer+94%270,270 @ $0.3700$100K
Analysts, earnings and news
Analysts' price target
$12.00 average
3 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
2 of 3 quarters above
Q2 '26−$1.40 a share+$0.15
Q1 '26−$3.54 a share−$1.88
Q3 '25−$0.68 a share+$5.90